Table 3.

Association of genotypes of chromosome 8q24 markers with prostate cancer risk stratified by Gleason score

AlleleControls (n = 535), n (%)Cases: Gleason 2 - 6 and 7 = 3 + 4 (n = 491)
Cases: Gleason 7 = 4 + 3 and 8 - 10 (n = 73)
n (%)OR* (95% CI)OR (95% CI)n (%)OR* (95% CI)OR (95% CI)
DG8S737
    X/X476 (89.0)430 (87.6)1.00 (reference)1.00 (reference)62 (84.9)1.00 (reference)1.00 (reference)
    −8/X or −8/−859 (11.0)61 (12.4)1.07 (0.88-1.29)1.08 (0.88-1.33)11 (15.1)1.19 (0.84-1.69)1.22 (0.86-1.73)
DG8S737
    X/X516 (96.4)467 (95.1)1.00 (reference)1.00 (reference)64 (87.7)1.00 (reference)1.00 (reference)
−10/X or −10/−1019 (3.6)24 (4.9)1.17 (0.86-1.60)1.13 (0.82-1.56)9 (12.3)1.93 (1.27-2.93)1.86 (1.22-2.83)
Allele
Controls (n = 538), n (%)
Cases: Gleason 2 - 6 and 7 = 3 + 4 (n = 504)
Cases: Gleason 7 = 4 + 3 and 8 - 10 (n = 75)
n (%)OR* (95% CI)OR (95% CI)n (%)OR* (95% CI)OR (95% CI)
SNP (rs1447295)
    CC427 (79.4)383 (76.0)1.00 (reference)1.00 (reference)50 (66.7)1.00 (reference)1.00 (reference)
    CA or AA111 (20.6)121 (24.0)1.10 (0.95-1.27)1.15 (0.98-1.34)25 (33.3)1.37 (1.05-1.78)1.41 (1.08-1.84)
Allele
Controls (n = 531), n (%)Cases: Gleason 2 - 6 and 7 = 3 + 4 (n = 485)
Cases: Gleason 7 = 4 + 3 and 8 - 10 (n = 72)
n (%)OR* (95% CI)OR (95% CI)n (%)OR* (95% CI)OR (95% CI)
DG8S737/SNP (rs1447295)
    XX/CC418 (78.7)366 (75.4)1.00 (reference)1.00 (reference)47 (65.3)1.00 (reference)1.00 (reference)
    XX/CA or AA94 (17.7)95 (19.6)1.15 (0.84-1.58)1.30 (0.91-1.85)17 (23.6)1.67 (0.93-3.00)1.74 (0.95-3.19)
    −10X or −10−10/CC2 (0.4)2 (0.4)1.28 (0.18-9.17)1.51 (0.18-12.98)0 (0.0)
    −10X or −10−10/CA or AA17 (3.2)22 (4.5)1.44 (0.75-2.76)1.55 (0.75-3.17)8 (11.1)3.94 (1.61-9.63)3.71 (1.46-9.44)
  • NOTE: Men with missing data for DG8S737 marker (30 cases/13 controls) or the SNP (rs1447295; 15 cases/10 controls) or prostate cancer cases with missing information on Gleason score (n = 3) were excluded from respective analyses.

  • * Models are adjusted for age.

  • Models are adjusted for age, first-degree relative with prostate cancer, and prostate cancer screening history.

  • The X defines the group of alleles in DG8S737 other than the allele of interest; Gleason score was obtained from biopsy pathology reports (29.5% of cases) or from surgical pathology reports for cases who had a radical prostatectomy (70.5%).